Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
deals
8
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
8
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
startups
alzheimer's disease
cancer
cancer immunotherapy
clinical trials
johnson & johnson
pfizer
abbvie
biogen
eli lilly
gilead sciences
merck
What
drug
8
×
roundup
bio
news
companies
nash
acquisitions
alzheimer’s
biggest
biogen’s
ceo
fda
gene
moves
patients
price
prices
road
today
week
aducanumab
ahead
albert
ambien
american
amyloid
angst
annual
approval
approved
aren’t
asco
attendees
attention
bagged
billions
biogen
biopharmaceutical
biotech
bourla
Language
unknown
unset
Current search:
drug
×
deals
×
photo
×
" indiana top stories "
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
6 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More